Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study

Guarneri, Valentina; Bassan, Franco; Zagonel, Vittorina; Milella, Michele Stanislaw; Zaninelli, Marta; Cattelan, Anna Maria; Vianello, Andrea; Gori, Stefania; Aprile, Giuseppe; Azzarello, Giuseppe; Chiari, Rita; Favaretto, Adolfo; Oliani, Cristina; Scola, A.; Pastorelli, Davide; Mandarà, Marta; Zustovich, Fable; Bernardi, Daniele; Chiarion-Sileni, Vanna; Morandi, Paolo; Toso, Seema; Liso, Elisabetta Di; Ziampiri, Stamatia; Caccese, Mario; Zampiva, Ilaria; Puccetti, Oliviero; Celestino, Michele; Dieci, Maria Vittoria; Conté, Pierfranco

doi:10.1016/j.ejca.2021.01.021

Cited by 15 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is not clear to what extent this comorbidity affects the cellular mechanisms observed in both diseases. While cancer patients infected with SARS‐CoV‐2 are known to be at increased risk, the human metabolic response to SARS‐CoV‐2 infection in cancer cells remains largely uncharacterised to date [ 3 , 4 , 5 , 6 ]. The severity of physiological symptoms experienced by individuals is largely dependent on the host response, which means understanding the metabolic changes caused by infection is crucial to identifying treatments for managing both the immediate and longer‐term effects on health [ 7 ].…”

Section: Figmentioning

confidence: 99%

Genome‐scale metabolic modelling of SARS‐CoV‐2 in cancer cells reveals an increased shift to glycolytic energy production

et al. 2021

View full text Add to dashboard Cite

Cancer is considered a high‐risk condition for severe illness resulting from COVID‐19. The interaction between severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) and human metabolism is key to elucidating the risk posed by COVID‐19 for cancer patients and identifying effective treatments, yet it is largely uncharacterised on a mechanistic level. We present a genome‐scale map of short‐term metabolic alterations triggered by SARS‐CoV‐2 infection of cancer cells. Through transcriptomic‐ and proteomic‐informed genome‐scale metabolic modelling, we characterise the role of RNA and fatty acid biosynthesis in conjunction with a rewiring in energy production pathways and enhanced cytokine secretion. These findings link together complementary aspects of viral invasion of cancer cells, while providing mechanistic insights that can inform the development of treatment strategies.

show abstract

Section: Figmentioning

confidence: 99%

Genome‐scale metabolic modelling of SARS‐CoV‐2 in cancer cells reveals an increased shift to glycolytic energy production

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We herein report the results of Veneto Institute of Oncology -Irccs survey about impact of the Covid-19 pandemic on cancer patients. Veneto Institute of Oncology has been engaged since the beginning of the pandemic in assessing epidemiology and clinical course of COVID-19 in cancer patients, with a first report by Guarneri et al 15 describing the characteristics of patients with cancer and SARS-CoV-2 infection within the Veneto Oncological Network. Out of 170 patients, hospitalization was necessary for 77%, with 6% requiring intensive care Unit admission; at the time of the analysis 33% of the patients had died and 17% of these from causes directly related to the infection.…”

Section: Discussionmentioning

confidence: 99%

Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology

Caccese¹,

Imbevaro²,

Feltrin³

et al. 2022

PPA

Self Cite

View full text Add to dashboard Cite

The SARS-CoV-2 spread has impacted Healthcare systems. COVID-19 pandemic has had consequences for patients with cancer, being associated with delays in diagnosis, in treatment And follow-up care, increase in overall infection rates and higher mortality. A survey on COVID-19 and a vaccination-questionnaire were developed at different times of the outbreak, to evaluate cancer patient-reported experience measures (PREMs) on the policies implemented to reduce the infection from SARS-CoV-2 and on the timing and methods of COVID-19 vaccination. Patients and Methods:The survey was distributed to all patients accessing the Institute during the "first-wave" Of the pandemic, evaluating patients' concerns about the pandemic, the pandemics' consequences on their cancer care, and their perception Of the measures adopted to limit the infection spread. The vaccination-questionnaire was proposed to 10% of the first 5297 cancer patients vaccinated with two doses of the Pfizer-BioNTechCOVID-19 vaccine. This questionnaire aimed at assessing the degree Of satisfaction with the Institutional vaccination campaign and vaccination-related adverse events. Results: From May 18th 2020 to June 15th 2020 the survey was completed by 3238 patients. Most of the responders expressed concern on the pandemic yet acknowledging their oncological disease as a priority. Measures implemented were appreciated by patients. Telemedicine was positively evaluated and the absence of the caregiver during the visit did not determine discomfort for two thirds of patients. From March 6th 2021 to May 8th 2021 the vaccination-questionnaire was completed by 357 patients. The 98.8% were satisfied with the vaccination campaign. No serious vaccination-correlated adverse events were reported. No patient had to delay/discontinue chemotherapy due to vaccination. Conclusion: PREMs during COVID-19 pandemic and related vaccination can provide important information to help reorganization of the health care systems for cancer care. Patients' feedback on the organizational changes implemented in the emergency period are essential for healthcare improvement and to help informed choices that are consistent with patients' needs.

show abstract

“…Morbidity and mortality from COVID-19 in patients with cancer undergoing cancer-directed treatment are high, with approximately one-third of patients experiencing severe course of disease, approximately three quarters requiring hospitalization, with mortality rates of approximately 30%. 1 , 2 Patients with hematologic cancer have been shown to have higher mortality compared with patients with solid cancer. 1-3 …”

Section: Introductionmentioning

confidence: 99%

Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Few data are available on the safety of COVID-19 vaccines in cancer patients undergoing active cancer-directed treatment. Patients and Methods This case series analyzes outcomes in terms of adverse events in 5297 patients undergoing anti-cancer treatment who were vaccinated with anti-SARS-CoV-2 Pfizer-BioNTech vaccine at a single cancer center from March 6, 2021 to May 9, 2021. Adverse events were retrieved from the national Italian pharmacovigilance platform (http://www.vigicovid.it). Results Of the 5297 patients treated for either solid tumors (87%) or onco-hematologic malignancies (13%) who were vaccinated, 8 adverse drug reactions (ADRs) were reported. One was a severe ADR and 7 were non-severe ADRs. Non-severe ADRs resolved within 48 hours. Conclusion BNT162b2 Pfizer-BioNTech vaccine was safely administered in the largest cohort of cancer patients reported to date.

show abstract

Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study

Cited by 15 publications

References 24 publications

Genome‐scale metabolic modelling of SARS‐CoV‐2 in cancer cells reveals an increased shift to glycolytic energy production

Genome‐scale metabolic modelling of SARS‐CoV‐2 in cancer cells reveals an increased shift to glycolytic energy production

Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology

Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center

Contact Info

Product

Resources

About